



BEKEMV™ (eculizumab) Vaccination/Antibiotic Prophylaxis Certificate

▼ This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on +44 (0) 1223 436441.

Commitment

- I, the undersigned, _____ hereby undertake to ensure and confirm that: I must explain BEKEMV treatment for PNH/aHUS to the patient/parent(s)/legal guardian(s) and I must deliver to the patient/parent(s)/legal guardian(s) all necessary information, including the Patient Safety Card and relevant patient educational materials before treatment initiation.
- I understand for patients on treatment with BEKEMV the vaccination status against meningococcus must be kept up to date, according to current national vaccination guidelines or if vaccination against meningococcal disease is contraindicated or not possible the patient should receive antibiotic prophylaxis from day 1 of treatment with BEKEMV and throughout the duration of the treatment period.
- I understand that I can request additional copies of BEKEMV educational materials consisting of: Patient Safety Card, Physician's Guide, Patient's/Parent's Information Brochure by contacting Amgen Medical Information by email at gbinfo@amgen.com or telephone 01223 436441.

Sorbitol Warning

- I understand that BEKEMV contains sorbitol and is therefore contraindicated in babies and young children below 2 years of age since they may not yet be diagnosed with hereditary fructose intolerance (HFI). Patients with HFI must not be given this medicine unless strictly necessary. After intravenous administration of a sorbitol containing medicine like BEKEMV, patients with HFI may present with severe metabolic abnormalities and life threatening symptoms including hypoglycaemia, metabolic acidosis, seizures, coma

Patient's Privacy Statement

- I hereby undertake to inform the patient, that for the purposes of supplying BEKEMV, Amgen will process their pseudonymised personal data and the patient can read details of the processing and protection of personal data, as well as his/her rights, in the Privacy Statement available on <https://www.amgen.co.uk/privacy-and-terms/privacy-statement>

Date: (DD-MM-YYYY) Signature:

Please read all information and check all 4 boxes.
Insert name of prescriber.